Affinity chromatography-mass spectrometry can directly detect cardiac troponin complexes in human serum post-AMI, potentially aiding personalized risk stratification and diagnostic reference material development.
May support future troponin assay refinement and risk stratification post-AMI; leaves open clinical utility pending prospective validation.
Affinity chromatography-mass spectrometry allows the extraction and analysis of cardiac troponins from biological samples in their natural forms. We were, for the first time, able to directly confirm the presence of cardiac troponin complexes in human serum after AMI. This approach could assist in more personalized risk stratification as well as the search for reference materials for cardiac troponin diagnostics.
No takes yet. Share an insight, caveat, or question.
Labugger et al. (2003) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: